All articles tagged with #alzheimers
Scientists developed a tool to temporarily boost mitochondrial activity in the brain, and in mouse models of neurodegenerative disease this restored memory performance, suggesting energy failure in neurons may drive cognitive decline and could become a new therapeutic target—though the approach is still far from human use and requires extensive safety and efficacy studies.
A long-running Adventist Health Study-2 found that regular egg consumption is associated with a lower risk of Alzheimer's disease in older adults, with those eating eggs two to four times per week about 20% less likely and five or more times per week about 27% less likely, after adjusting for age and lifestyle. The nutrients in eggs—choline, omega-3s, and vitamin B12—may support brain health, but the study does not prove causation and may not generalize beyond health-conscious populations; more research is needed to understand how diet affects brain health.
A Mayo Clinic study finds Alzheimer’s-related changes can begin in people’s late 50s, decades before memory problems, outlining a two-phase timeline where amyloid buildup appears first, followed by other biomarkers and cognitive changes as people age, with blood and imaging signals peaking later. The research warns that averages don’t predict an individual's onset and suggests earlier, smarter screening and planning, while noting limitations in population diversity and the need for clearer clinical guidelines.
Alzheimer’s breakthroughs are advancing scientifically, with drugs like Lecanemab and Donanemab showing amyloid removal and slowed decline, but experts say real progress hinges on better, earlier diagnosis through biomarkers and genetics, plus sustained political investment in dementia services to ensure access and implementation across healthcare systems.
Alzheimer's blood tests that detect amyloid or tau are being considered for early risk assessment, but doctors say their predictive value for asymptomatic people is uncertain, with potential false positives/negatives and no clear benefit from early intervention; FDA has cleared two tests for symptomatic patients, not for screening; patient interest is high, with surveys showing many would take a test if advised, though distress is common.
UCSD researchers used an AI-driven approach to identify chromogranin A as a molecular switch deciding whether Alzheimer’s pathology translates into memory loss. In tauopathy mice, removing CgA preserved learning and memory despite brain pathology, with females showing stronger protection. They also found catestatin, a peptide derived from CgA, which lowered disease markers and protected cognition across several mouse models. All findings are preclinical and require replication, dosing, safety studies, and regulatory review before any human testing, but the work aims to shift Alzheimer’s research toward prevention-based strategies.
UC Irvine researchers find dopamine loss in the entorhinal cortex impairs memory in Alzheimer’s models; restoring dopamine with Levodopa (and optogenetics) re-enables memory, signaling a fast-track, dopamine-based therapy path that could supplement protein-clearing strategies.
Researchers report a 40-gene pattern that distinguishes normal aging, symptomatic Alzheimer's, and a resilient state, and identify Chromogranin A (CgA) as a stress-related protein that links cellular stress to Tau tangles. In mice, removing CgA reduced Tau buildup and preserved memory, especially in females, suggesting resilience pathways can sustain cognition despite brain damage. While promising, these findings are in animals and must be validated in humans, with resilience markers potentially guiding early prevention.
A Mass General Brigham-led study shows a blood test measuring pTau217 can predict Alzheimer's risk years before symptoms appear, potentially enabling earlier, less invasive screening than PET scans; while promising, more research is needed to validate across diverse populations and translate these findings into clinical practice.
FDA plans advisory panels to reconsider compounded peptides; a sweeping Cochrane review revives debates over amyloid-targeting Alzheimer’s drugs; Roche will run another Elevidys trial outside the U.S. as Sarepta markets it domestically; Lilly’s Foundayo GLP-1 pill shows non-inferiority to insulin glargine with a FDA submission planned by the end of Q2.
A Cochrane review of 17 trials with over 20,000 people with mild cognitive impairment or early dementia found that seven anti-amyloid drugs, including donanemab and lecanemab, do not deliver a clinically meaningful benefit, even though they reduce brain amyloid. The findings challenge the idea that removing amyloid improves patient outcomes and have fueled ongoing debate over the amyloid hypothesis and the drugs’ high costs and risks.
A new Cochrane analysis of 17 trials (over 20,000 participants) finds amyloid-beta–targeting monoclonal antibodies, including Leqembi and Kisunla, likely confer little to no meaningful cognitive or functional benefit in mild cognitive impairment or mild Alzheimer's, while modestly increasing the risk of ARIA-E (brain swelling); despite some trial-specific benefits for individual drugs, the overall class effect is in doubt, prompting calls to pursue other disease mechanisms.
A Cochrane Collaboration analysis of 17 trials involving over 20,000 people finds that amyloid-clearing Alzheimer's drugs slow decline but do not meaningfully improve patients’ lives, while carrying risks and costing up to £90,000 for an 18‑month course; the findings have sparked debate among experts, with some arguing for nuanced interpretation and others defending potential benefits, and the NHS continuing not to fund them.
Penn State researchers are using interpretable AI to analyze everyday speech for subtle linguistic changes that signal cognitive decline, enabling screening for Alzheimer’s in under a minute—more objective and scalable than traditional tests and capable of integration into routine care with plans to expand to additional signals and care settings.
A Paris charity raffle offers Picasso’s 1941 gouache 'Tête de Femme' as the prize for €100 tickets, aiming to sell up to 120,000 entries and raise as much as €12 million. Of that, €1 million goes to Opera Gallery (the painting’s owner) and the rest to medical research via the Alzheimer’s Research Foundation. The draw is on 14 April at Christie's Paris, with the artwork on public display beforehand; past raffles in 2013 and 2020 raised over €10 million for various causes.